Guardant Health’s Post

The field of financial navigation....such an important role.

Great insights on a topic that’s top of mind for all clients.

Great Insight here! A very important read. https://lnkd.in/ggNb3ju6

In decision analysis, we must avoid binary choices when making a decision. According to dr. Paul Nutt, one reason for decision failure is a lack of alternatives. Therefore, we should consider more alternatives in our decision (we will detail this issue more later). The following international paper (see the link for a request, please) addresses this issue by evaluating different percentage of Less Than Truckload (LTL) against Full Truckload (TL) cargo, considering total logistics costs, and benefits. We used Multi-Criteria Decision Analysis approach (#MCDA) combined with #Mathematicalmodelling (i.e., Goal Programming) for structuring and appraising these transportation modes of a large and complex Joint Transportation and Inventory Problem (JTIP). We also considered group decision and risk aversion for the decision-markers in this decision problem. It was a case study conducted in the SKY company to evaluate the #logistics costs (#Custologistico). We tested the efficiency of the approach in this real situation, also considering the evaluation of several qualitative criteria regarding the benefits. Thank the SKY team for the opportunity to work together on this project! https://lnkd.in/gPSypKRj

OmniAb, Inc. has reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates. The company signed 10 new licenses in 2023, including three in the fourth quarter, with Enable Life Sciences, Mirador Therapeutics, and a global pharma company. In addition, six new OmniAb-derived antibodies entered the clinic in 2023. Among the partnered programs notes: Genmab expects to announce additional acasunlimab (GEN1046: PD-L1 x 4-1BB) Phase 2 data in second-line non-small cell lung cancer (NSCLC) in the first half of 2024. In addition, Genmab plans to initiate a Phase 3 study of acasunlimab in a second-line NSCLC indication in 2024. #mabs https://lnkd.in/gNBb94Ri

Beyond Air® Reports Financial Results for Third Quarter of

Our latest Annual Report is now available on our website, highlighting progress and patient stories in our relentless pursuit of eliminating prostate cancer. Together, we're combatting stigma, championing early detection, and empowering and supporting patients. As we continue to see a rise in diagnoses in 2024, we will be louder and bolder in our mission to improve outcomes for all people impacted by #prostatecancer. #ZEROProstateCancer #AnnualReport

Paper from our lab discussing how MGA delegation drives Richter’s transformation. Very interesting and informative. https://lnkd.in/g9EFpVKE

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Beyond Air® Reports Financial Results for Third Quarter of